Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.

Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery.

Verona Pharma PLC (NASDAQ:VRNA) shares have reached an all-time high, touching a price level of $62.09. According to ...

Sun Pharma is currently trading at Rs 1740.15, showing a slight decline of 0.22% today, with weekly returns down by 4.68%.

Vertex Pharmaceuticals continues to execute ... conservative analyst revenue projections, making the stock a STRONG BUY with a 12-month price of $550/share. As of yesterday evening, the FDA ...

Sales in the Pharmaceuticals Division grew 8% in 2024 ... Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability ...

Vertex set the U.S. wholesale price of Journavx at $15.50 per 50mg pill. Shares of Vertex Pharmaceuticals (VRTX) surged Friday, a day after the drugmaker reported federal regulators have approved ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform rating on the shares. The FDA approval of Suzetrigine ...

This anticipated adoption, along with a projected modest market penetration, underpins the increased price target for Vertex Pharmaceuticals’ stock, contributing to Fein’s Buy rating.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...